Jinghua Pharmaceutical Group Co Ltd was established through the restructure of Nantong Zhongcheng Pharmaceutical Co Ltd (Nantong Chinese Medicine Factory) and Nantong General Pharmaceutical Co Ltd (Nantong Pharmaceutical Co Ltd and the second branch of Nantong Pharmaceutical Co Ltd) with investment from Nantong Zongyi Investment Co Ltd and private investors.

In February 2010, the company was listed on Shenzhen Stock Exchange (stock code: 002349).

Jinghua has been engaged in medicine production for over 60 years and has always been a government-oriented pharmaceutical company. Currently, as a comprehensive and modernized GMP company, Jinghua has become the main force of production, sales and development of APIs, intermediates and formulations in China, and is also involved in biomedicine. It produces more than 200 kinds of Chinese and Western medicines. Four API products have earned the Certificate of Suitability and two APIs have gained approval of the US Food and Drug Administration (USFDA).

All products are in accordance with GMP and carefully implement ChP (Pharmacopoeia of the People's Republic of China), EP (European Pharmacopoeia), BP (British Pharmacopoeia) and USP (United States Pharmacopeia) for the quality of APIs.